video.Alia Hadefi_DMR_December.m4v (268.86 MB)
Supplementary Material for Endoscopic Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes
Version 3 2018-04-20, 09:01
Version 2 2018-04-20, 08:29
Version 1 2018-04-20, 08:26
media
posted on 2018-04-20, 09:01 authored by Alia Hadefi, Vincent Huberty, Arnaud Lemmers, Marianna Arvanitakis, David Maggs, Guido Costamagna, Jacques DevièreType 2 diabetes is a pandemic disease with an incidence that
has risen steadily over recent decades. Experimental evidence
in animals has demonstrated that intestinal bypass
surgery of the upper small intestine, particularly the duodenum,
has an important role in glucose homoeostasis. Furthermore,
Roux-en-Y bypass performed as bariatric surgery
has shown to correct hyperglycaemia from the first postoperative
days in obese diabetic patients. Therefore, on the basis
of these considerations, duodenal mucosal resurfacing
was studied in type 2 diabetes patients as a minimally invasive
procedure that could offer an alternative treatment for
these patients. Further studies, and particularly large controlled
trials, are needed to determine the place of this procedure
in the treatment of type 2 diabetes as well as other
metabolic diseases such as non-alcoholic fatty liver disease/
non-alcoholic steatohepatitis.
has risen steadily over recent decades. Experimental evidence
in animals has demonstrated that intestinal bypass
surgery of the upper small intestine, particularly the duodenum,
has an important role in glucose homoeostasis. Furthermore,
Roux-en-Y bypass performed as bariatric surgery
has shown to correct hyperglycaemia from the first postoperative
days in obese diabetic patients. Therefore, on the basis
of these considerations, duodenal mucosal resurfacing
was studied in type 2 diabetes patients as a minimally invasive
procedure that could offer an alternative treatment for
these patients. Further studies, and particularly large controlled
trials, are needed to determine the place of this procedure
in the treatment of type 2 diabetes as well as other
metabolic diseases such as non-alcoholic fatty liver disease/
non-alcoholic steatohepatitis.
